Asparaginase



Indications and Reactions:

Role Indications Reactions
Primary
Acute Lymphocytic Leukaemia 55.6%
Non-hodgkin's Lymphoma 12.2%
B Precursor Type Acute Leukaemia 8.9%
Product Used For Unknown Indication 7.8%
Lymphoma 2.2%
Natural Killer-cell Lymphoblastic Lymphoma 2.2%
Acute Leukaemia 1.1%
Angiocentric Lymphoma 1.1%
Angioimmunoblastic T-cell Lymphoma 1.1%
Chloroma 1.1%
Lymphocytic Leukaemia 1.1%
Precursor B-lymphoblastic Lymphoma 1.1%
Precursor T-lymphoblastic Lymphoma/leukaemia 1.1%
Prophylaxis 1.1%
T-cell Lymphoma 1.1%
T-cell Type Acute Leukaemia 1.1%
Pancreatitis Acute 17.0%
Hyperglycaemia 8.5%
Hyperlipidaemia 8.5%
Pancreatitis 8.5%
Pancreatitis Necrotising 6.4%
Hypersensitivity 4.3%
Hypertriglyceridaemia 4.3%
Intracranial Venous Sinus Thrombosis 4.3%
Leukopenia 4.3%
Liver Disorder 4.3%
Protein Total Decreased 4.3%
Thrombosis 4.3%
Tumour Lysis Syndrome 4.3%
Vomiting 4.3%
Blood Triglycerides Increased 2.1%
Cerebral Thrombosis 2.1%
Cerebral Venous Thrombosis 2.1%
Congenital Aplastic Anaemia 2.1%
Convulsion 2.1%
Embolism Venous 2.1%
Secondary
Acute Lymphocytic Leukaemia 69.1%
Chromosome Analysis Abnormal 7.2%
B Precursor Type Acute Leukaemia 4.5%
Product Used For Unknown Indication 2.7%
Prophylaxis 2.4%
Precursor T-lymphoblastic Lymphoma/leukaemia 1.5%
T-cell Type Acute Leukaemia 1.4%
Antifungal Prophylaxis 1.2%
Haematological Malignancy 1.2%
Lymphocytic Leukaemia 1.2%
Drug Use For Unknown Indication 1.1%
Acute Myeloid Leukaemia 0.9%
Precursor B-lymphoblastic Lymphoma 0.8%
Natural Killer-cell Lymphoblastic Lymphoma 0.8%
Non-hodgkin's Lymphoma 0.8%
Chemotherapy 0.7%
Prophylaxis Against Graft Versus Host Disease 0.7%
B-cell Type Acute Leukaemia 0.7%
Lymphoma 0.6%
T-cell Lymphoma 0.5%
Off Label Use 13.6%
Renal Vein Thrombosis 10.8%
Thrombosis 9.2%
Sepsis 6.0%
Zygomycosis 6.0%
Posterior Reversible Encephalopathy Syndrome 5.2%
Glioma 4.8%
Reversible Posterior Leukoencephalopathy Syndrome 4.8%
Venous Thrombosis 4.8%
Staphylococcal Infection 4.4%
Vomiting 4.4%
Subclavian Vein Thrombosis 4.0%
Neutropenia 3.2%
Hepatotoxicity 2.8%
Hypotension 2.8%
Pancreatitis 2.8%
Thrombocytopenia 2.8%
Treatment Related Secondary Malignancy 2.8%
Anaphylactic Reaction 2.4%
Cardiac Failure Congestive 2.4%
Concomitant
Acute Lymphocytic Leukaemia 36.4%
Lymphoma 18.6%
Product Used For Unknown Indication 9.7%
Precursor T-lymphoblastic Lymphoma/leukaemia 4.5%
B Precursor Type Acute Leukaemia 4.1%
Antifungal Prophylaxis 3.4%
Chemotherapy 2.9%
Diffuse Large B-cell Lymphoma Stage Iii 2.6%
Gastritis Prophylaxis 2.6%
Acute Leukaemia 2.5%
Bone Marrow Conditioning Regimen 2.2%
Prophylaxis Against Graft Versus Host Disease 2.2%
Leukaemia 1.8%
Angioimmunoblastic T-cell Lymphoma 1.5%
B-cell Lymphoma Stage Iii 1.3%
Drug Use For Unknown Indication 0.9%
Prophylaxis 0.9%
Neoplasm Malignant 0.7%
Chronic Graft Versus Host Disease 0.6%
Epilepsy 0.6%
Retinal Vein Thrombosis 24.7%
Toxic Skin Eruption 9.6%
Toxicity To Various Agents 6.8%
Acute Respiratory Distress Syndrome 5.5%
Septic Shock 5.5%
Hemiparesis 4.1%
Neurotoxicity 4.1%
Stomatitis 4.1%
Thrombosis 4.1%
Viral Infection 4.1%
Cardio-respiratory Arrest 2.7%
Central Nervous System Lesion 2.7%
Cholestasis 2.7%
Conjunctivitis 2.7%
Epstein-barr Virus Associated Lymphoproliferative Disorder 2.7%
Hyperglycaemia 2.7%
Monoparesis 2.7%
Pleural Fibrosis 2.7%
Pseudobulbar Palsy 2.7%
Renal Tubular Necrosis 2.7%
Interacting
Acute Lymphocytic Leukaemia 83.3%
Neoplasm 16.7%
Hypofibrinogenaemia 50.0%
Somnolence 50.0%